PSS26 PATIENT'S EVALUATION OF THE QUICKNESS OF ACTION OF GINGIVAL INFLAMMATION TREATMENTS  by Mattout, P. et al.
who used combination therapy (topical corticosteroid and TCI) (68%). Type of
health plan, Medicaid eligibility status, number of therapeutic class, comorbidity,
hospitalization or not andAD related costs during 12months before ADmedication
started were significantly associated with ADmedication adherence. Adherence to
AD medication was significantly negatively associated with total annual health-
care costs (p0.001) and with AD related costs (p0.001), adjusted for patient de-
mographic, comorbidity, and healthcare utilization characteristics before ADmedica-
tion started.CONCLUSIONS: Poor adherence to topical medication was observed in
pediatric AD, and adherence rates differed by the type and combination of AD
medication therapy. The detrimental effect of poor adherence on healthcare eco-
nomic outcome was significant, which implies a need to improve adherence in
order to reduce the financial impact of non-adherence. Factors which could con-
tribute non-adherence and financial burden need to be refined and targeted by
intervention to improve humanistic and economic outcomes of treatment.
PSS26
PATIENT’S EVALUATION OF THE QUICKNESS OF ACTION OF GINGIVAL
INFLAMMATION TREATMENTS
Mattout P1, Rahhali N2, Watt M3, Auges M2, Taieb C2
1GEPI, Marseille, France, 2PFSA, Boulogne Billancourt, France, 3PFOC, Castres, France
OBJECTIVES: Gingivitis is defined as lesions on the gingival margin, expressed
through gum redness, bleeding, localized edema, and gingival sensitivity. It ismost
often caused by substances produced by bacterial plaque, or dental biofilm, which
develops along the gingival crevice.To evaluate, using patient’s interview results,
the quickness of action of several treatments for gingival inflammation.
METHODS:Observational, prospective, longitudinal,multicentric study carried out
in France, using data collected by participating dentists and dental surgeons.
RESULTS:A total of 316 patientswith gingivitis returned their questionnaire. wom-
en: 65.25%, current smokers:22.93% and 28.51% were ex-smokers. Light and heavy
bleeding during brushing was reported by 45.74% and 33.33% of patients respec-
tively. 45.70% reported visible redness, 56.34% reported swollen gums, 13.19% had
lesions, but above all 50.52% reported pain. Finally, 62.26% had previous history of
gingivitis symptoms. As for dental surgeons: 96.36% had performed scaling, 15.15%
gingival curettage, and 13.64% radicular resurfacing. A total of 78.4% judged gingi-
val inflammation to be moderate to severe, 63.10% said it had spread (30%). In
terms of treatment: 98.62% gave patients oral hygiene advice, 87.98% advised on
brushingmethods, 69.91% recommended specific toothpaste, and 78.85% amouth-
wash. A total of 30.61% had generalized inflammation after 1 month, reducing to
just 11.24% at 2months and 15.63% at 3months. A total of 88.08% reported improve-
ment in inflammation after the first month, 91.59% at 2 months and 93.59% at 3
months. A total of 83.93% felt less pain after 1 month of treatment, 87.90% after 2
months and 92.08% after 3 months.(p0.0418). 89.13% felt their treatment was effec-
tive after 1month, 97.79% after 2 months and 96.15% after 3 months.(p0.0036).
CONCLUSIONS: In terms of satisfaction, 86.52% were satisfied after 1 month, 94.85%
after 2months and 95.92% after 3months. (p0.0076). 87.57% felt their treatmentwas
easy to follow after 1month, 86.76% after 2months and 92.08% after 3months. Above
all, after the first month of treatment, 88.83% said they would continue using the
treatment in prevention even after complete disappearance of gingivitis.
Sensory Systems Disorders – Research on Methods
PSS27
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OBJECTIVES: To evaluate the effect of treatment switch on the cost-effectiveness
of biologics used in patients with moderate or severe psoriasis in Colombia and
Perú. METHODS: In a previous study (Alandete, JC accepted in the ISPOR 13th
Anual European Congress) cost effectiveness of etanercept, adalimumab,
ustekinumab and infliximab was estimated based on label information for first-
(induction) year and second(maintenance) year assuming a 100% treatment
continuation ($1USDCOL$1.832SOL$2.75). For etanercept two induction
schemes were considered: 50mg weekly 52 weeks-D1- and 100mg 12 weeks fol-
lowed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in
Psoriasis Area and Severity Index-PASI 75- infliximab80%; ustekinumab69%;
adalimumab59%; etanerceptD2-52%; etanerceptD139%. Infliximab and
ustekinumab effectiveness were not significantly different. Both were significantly
superior to etanercept (Hawkins et al. meta-analysis presented in the 14th Interna-
tional ISPOR). In this abstract we developed a new model estimating switching
probabilities due to treatment failure atweek 12 and adverse events. Biologics costs
were adjusted considering time on the pre and post-switching periods. Treatment
effectiveness was adjusted when biologics were used after switching due to treat-
ment failure. RESULTS: Introduction of switching effect ratified ustekinumab dom-
inance in Colombia ($US44,675 in 2 years) generating cost savings of -$US4.049
versus etanerceptD1; -$US4.049 versus adalimumab; -$US7.844 versus etaner-
ceptD2 and -$US27.517 versus infliximab; with higher or same effectiveness than
the other biologics in that country. In Peru, ustekinumab changed from being the
most cost-effective option and became the dominant option ($US41.827 in 2 years)
generating cost savings of -$US283 versus etanerceptD1; -$US489 versus adali-
mumab; -$US3581 versus etanerceptD2 and -$US13.499 versus infliximab.
CONCLUSIONS: In the studied countries inclusion of the switching effect due to
treatment failure and adverse events ratifies cost-savings observed in Colombia
and makes ustekinumab the cost-saving option in Peru. These results corroborate
those observed in the USA and Europe.
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OBJECTIVES: Clinical studies of dry eye disease (DED), a highly symptomatic dis-
ease, often ask patients to evaluate their DED symptoms using patient-reported
outcomes instruments. Most of these instruments use a one-week recall period.
The effect of this recall period on the accuracy of DED symptom assessments has
not been documented. The purpose of our research was to compare self-reported
DED symptoms between one-week and daily recall periods. METHODS: We en-
rolled 156 DED patients to a web-based observational study to assess their DED
symptoms once a day for 9 days. For each of the 14 symptoms, we asked the
patients to rate the frequency and intensity on a 0-6 rating scale, with a higher
score indicatingworse symptom. The assessments onDays 1 and 9 had a one-week
recall period, while the assessments on Days 2-8 had a one-day recall period. We
then calculated the mean weekly scores for Day 1 and Day 9 and the mean daily
scores for Days 2-8, and tested the differences between themean weekly and daily
scores using matched-pair t tests without multiplicity adjustment. RESULTS: The
Day 1mean weekly scores were significantly higher than themean daily scores for
all 14 symptoms in both frequency and intensity. The Day 1 mean weekly scores
were also significantly higher than the Day 9 mean weekly scores in 10 frequency
and 11 intensity scores. The Day 9 mean weekly scores were slightly higher than
the daily scores; however, most of the differences were not statistically significant.
CONCLUSIONS: Patients’ self-ratings of their DED symptoms using a one-week
recall period are consistently inflated when compared to their ratings using a one-
day recall period. Such inflation should be considered when designing clinical
studies for DED.
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OBJECTIVES: Dry eye disease (DED) is characterized by symptoms of ocular dis-
comfort, visual disturbance and reduced tolerance to environmental stressors.
DED has a significant negative impact on the quality of life (QOL) of persons af-
fected, and imposes a massive burden on medical resources owing to its high
prevalence and chronic nature. It is not known if available patient-reported out-
come (PRO) instruments fully capture the scope of DED symptoms and their impact
on QOL. The purpose of our ongoing research is to develop a PRO instrument that
meets the needs of clinical studies investigating potential treatments for DED.
METHODS: Patients with DED in five countries (United States, United Kingdom,
Spain, Japan and Korea) were interviewed to identify their symptoms and the im-
pact of the disease on QOL (n120). Based on these results, itemswere drafted that
were tested in two web-based studies with mild-moderate DED subjects (n106
and 156) and face-to-face interviews with severe DED subjects (n22). RESULTS:
Items enquiring about 8 additional symptom experiences (16 items grouped in
doublets asking about frequency/intensity) were added to the original Ocular Com-
fort Index (OCI) using the same question format and response structure (fluctuat-
ing vision, light sensitivity, redness, foreign body sensation, excessive tearing, ex-
cessive blinking, ocular irritation and stickiness). Additionally, 2 items that
enquired about the most bothersome symptom and the extent of bother, and 12
items that appraised how symptoms interfered with the ability to perform daily
activities were included. CONCLUSIONS: Patient interviews suggest that available
PRO instruments do not fully capture the scope of DED symptoms and their impact
on QOL. The modified OCI (mOCI) will be used in clinical studies to facilitate its
refinement and validation.
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OBJECTIVES: Infantile hemangioma (IH) develops during the first weeks of life; it
normally forms within 3to6 months, then regresses very slowly over a duration of
3 to 7 years. In complicated forms, it is possible to encounter haemorrhaging,
necroses and ulcerations, infections and, more exceptionally, respiratory distress,
cardiovascular shunt. To explore the handicap, in its largest sense, generated by IH
using a questionnaire to express the burden on the daily life of the parents.
METHODS: The questionnaire was developed following a strict methodological
process, involving amultidisciplinary team incorporating various players (doctors,
nurses, social workers) who are involved in the treatment of patients or who are
specialised in the construction of questionnaires. A review of the literature and
discussions with the families were conducted in order to identify the concepts
related to the pathology. RESULTS: Exploratory assessments showed that the con-
cept of burden could be structured around two main modules: assess the impact
directly for the first-module. The consequences of HI on daily life, family and
personal relationships, work, financial situation and psychological impact for the
second-module. A third module focuses on the behaviour of the child; this module
will evolve over time and depending on the analyses. Fifty-six preliminary items
were identified following a first discussion. A first analysis managed to reduce
these items to 36 whilst conserving the 3 modules but making it easier to use the
analysis. CONCLUSIONS: The Hemangioma-Burden-Questionnaire will allow cli-
nicians to better understand the impact and consequences of the pathology on the
family. It will also allow the development of the burden to be monitored according
to the rate of development of the illness and its treatment.It will also allow the
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